Global Second Generation Cephalosporins Market Research Report 2022

Due to the COVID-19 pandemic, the global Second Generation Cephalosporins market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Second Generation Cephalosporins market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Second Generation Cephalosporins landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Cefotiam accounting for % of the Second Generation Cephalosporins global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Respiratory Tract Infection segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Second Generation Cephalosporins include Apotex, Esseti Farmaceutici, GSK, Lilly, Medochemie, Northeast Pharmaceutical, NCPC, Nanchang Lijian Pharmaceutical and Sichuan Pharmaceutical, etc. In terms of revenue, the global 3 largest players have a % market share of Second Generation Cephalosporins in 2021.
This report focuses on Second Generation Cephalosporins volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Second Generation Cephalosporins market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Second Generation Cephalosporins Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Cefotiam
Cefuroxime
Segment by Application
Respiratory Tract Infection
Otolaryngological Infection
Urinary Tract Infection
Skin and Soft Tissue Infections
Bone and Joint Infections
Gonorrhea
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Apotex
Esseti Farmaceutici
GSK
Lilly
Medochemie
Northeast Pharmaceutical
NCPC
Nanchang Lijian Pharmaceutical
Sichuan Pharmaceutical
Shandong Runze Pharmaceutical
Shandong Luoxin Pharmaceutical Group
Guangdong Bozhou Pharmaceutical
Guangdong Jincheng Jinsu Pharmaceutical
Guangzhou Baiyunshan Tianxin Pharmaceutical
Guangxi Kelun Pharmaceutical
Yuekang Pharmaceutical Group
Shantou Jinshi Injection
Zhejiang Yatai Pharmaceutical
Shenzhen Xinlitai Pharmaceutical
Shenzhen Huarun Jiuxin Pharmaceutical
Zhuhai Union Pharmaceutical
Ruiyang Pharmaceutical
Fujian Fukang Pharmaceutical
Suzhou Erye Pharmaceutical
Furen Pharmaceutical Group
Chongqing Kerui Pharmaceutical Group
Shanxi Xidunsi Pharmaceutical
Qilu Pharmaceutical
Shandong Zibo Xinda Pharmaceutical
Guangzhou Nanxin Pharmaceutical

Frequently Asked Questions